Latest News
Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story.
For media and press enquiries, please contact Louise Rowe at contact@resolution-tx.com
Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure patients can access treatment in the community setting, where the majorityof decompensated patients are managed RTX001 has the potential to be the first treatment that demonstrates a clear and durable improvement in transplant free survival for ESLD patients
Nottingham is investigating a first-in-class cell treatment to help patients End Stage Liver Disease
Decompensated cirrhosis has a poor prognosis and few treatment options, with liver transplantation available to only a small minority of patients. Resolution Therapeutics is investigating RTX001, an engineered Regenerative Macrophage Therapy, as a potential alternative to improve survival and quality of life.
EMERALD Clinical Study: Q&A with Dr Paul Richardson & Dr Edward Britton, Royal Liverpool University Hospital
Dr Paul Richardson and Dr Edward Britton describes the End-Stage Liver Disease patient population being treated in the EMERALD clinical study which is evaluating Regenerative Macrophage Therapy as a potential new treatment.
The EMERALD clinical study: an overview with Prof. Ewan Forrest, Glasgow Royal Infirmary
EMERALD is an early-stage clinical trial of an innovative cell therapy for patients with end-stage liver disease, taking place in the UK and Spain. The therapy being tested, called Regenerative Macrophage Therapy, is designed to help even badly damaged livers recover, thus preventing disease from progressing further.
EMERALD Clinical Study: Q&A with Dr Kushala Abeysekera, Bristol Royal Infirmary Hospital
Liver disease kills over 12,000 people in the UK and 52,000 in the US every year. Once advanced, half of patients die within a year — and only 3% receive a transplant. Dr Kush Abeysekera explains why the status quo isn't working, and why Resolution Therapeutics is developing RTX001 as a potential alternative. First in a series on regenerative medicine in liver disease.
Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy
Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy Development programme complements Company’s autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy
Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis
Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001
Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026
Resolution Therapeutics will present key preclinical data today on its Regenerative Macrophage Therapy RTX001 in an oral presentation at the ASGCT Annual Meeting, being held from 11-15 May, 2026, in Boston, Massachusetts, US.
Resolution Therapeutics’ VP, Intellectual Property & Technology Strategy Eli Gilsohn named in the World International IP Review (WIPR)’s Global In-House Elite 2026 list
VP, Intellectual Property & Technology Strategy Eli Gilsohn named in the World International IP Review (WIPR)'s Global In-House Elite 2026 list
Resolution Therapeutics announces appointment of Louise Rowe as Vice President of Operations
Resolution Therapeutics announces the appointment of Louise Rowe as Vice President of Operations
Love Your Liver Month 2026
As liver disease rises and treatment options remain scarce, Resolution Therapeutics is pioneering regenerative macrophage therapy to bring new hope to patients this Love Your Liver Month.